Researchers evaluated the efficacy and safety of abatacept in pediatric patients with polyarticular-course juvenile idiopathic arthritis.
Investigators analyzed the characteristic traits and risk factors of parenchymal lung disease, which has been increasingly associated with systemic juvenile idiopathic arthritis.
Researchers demonstrated the role of an inflammatory subset of CD4 memory cells in patients with juvenile idiopathic arthritis who are in remission and will relapse on anti-TNF withdrawal.
Researchers highlighted the use of pharmacologic stress cardiovascular magnetic resonance (PSCMR) in specific pediatric cohorts with congenital and acquired heart disease. They also presented 2 cases of patients with Kawasaki disease, in which PSCMR helped in decision making.
A comparative list of treatment options for arthritis including DMARDS and other immune modulators.
Researchers highlighted the clinical factors that reduce the sensitivity of inflammatory markers in the diagnosis of pediatric osteomyelitis.
Researchers evaluated Canadian claims level data to assess the utilization of methotrexate and prednisone in patients with JIA who initiated etanercept therapy.
Researchers assessed the efficacy and safety of leflunomide, as an alternative to methotrexate, in patients with juvenile idiopathic arthritis.
Researchers evaluated the efficacy of bisphosphonate risedronate vs alfacalcidol in steroid-induced osteopenia in children.
The study assessed the implications of genetic advances in juvenile idiopathic arthritis; the results of the research may be useful in the treatment of arthritis in children.